Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China7 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors | Advanced Solid Tumor | Recruiting | Phase 1 / Phase 2 | 2026-09-17 | NCT06953323 | |
| A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL. | chronic lymphocytic leukemia/small lymphocytic lymphoma | Recruiting | Phase 3 | 2026-07-28 | NCT06319456 | |
| Treatment of Recurrent/Metastatic Head and Neck Cancer | Head and Neck Neoplasms, Neoplasms by Site, neoplasm | Not yet recruiting | Phase 1 / Phase 2 | 2026-05-22 | NCT07601204 | |
| A Study Explore WJB001 Capsules in Patients With Advanced Solid Tumors | Advanced Solid Tumors | Recruiting | Phase 1 / Phase 2 | 2026-04-01 | NCT05773820 | |
| Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen | Neoplasm Metastasis, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, neoplasm | Recruiting | Phase 3 | 2026-02-06 | NCT06127407 | |
| A Study of GLB-002 in Patients With Relapsed or Refractory Non-Hodgkin Lymphomas | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, non-Hodgkin lymphoma | Recruiting | Phase 1 | 2025-08-19 | NCT06219356 | |
| A Clinical Trial Evaluating TQB2102 for Injection in Combination With Behmosubaisumab/Payamprolizumab With or Without Chemotherapy in Unresectable Locally Advanced, Recurrent, or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastroesophageal Adenocarcinoma | gastroesophageal adenocarcinoma | Recruiting | Phase 2 | 2025-07-30 | NCT06767800 |